BeOne Medicines
Headquarters country
Switzerland
Registry sponsor category
Industry
- Company name
- BeOne Medicines
- Organisation type
- Industry
- Registered legal name
- BeOne Medicines Ltd.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- BeOne Medicines
- BeOne Medicines LTD
- SEC filer number (CIK)
- 0001651308
Related records
Trials (80)
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
- A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
- A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
- A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
- A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
- A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
- A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
- A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- A Study of BG-C477 in Participants With Advanced Solid Tumors
- A Study of BGB-11417 in Participants With Myeloid Malignancies
- A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
- A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
- A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors